Company intelligence / Profile preview

Bila M

San Francisco, California, United Statesbila.com ↗

Ownership: Private
Employees: ~15
Development stage: Other

Overview

Bila is a biotechnology company focused on developing next-generation, long-acting therapies for the treatment and prevention of HIV. The company's lead programs utilize a novel mechanism of action targeting the HIV-1 capsid protein to inhibit viral replication. By focusing on ultra-long-acting formulations, Bila aims to reduce the dosing frequency for patients, potentially moving from daily pills to injections administered every few months. The company is leveraging expertise in medicinal chemistry and virology to address the limitations of current antiretroviral therapies.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Bila M.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bila M.

Explore the full profile